USFDA issues warning letter to Jubilant Lifesciences Ltd

As per the FDA requirement, the company will have to respond to this letter by 12th December this month. The response should contain the details of corrective actions and should identify that these actions have already being implemented. Also, enlisted should be the details of pending corrective actions that would be taken to comply with current good manufacturing practice standards (cGMP).
As per the companys announcement, this letter would not have any impact on the manufacturing, and sale or distribution of their products of this facility. The company is hopeful about resolving this mater by working closely with the FDA.